60 Degrees Pharmaceuticals (SXTP) EBIT (2022 - 2026)

60 Degrees Pharmaceuticals (SXTP) has reported EBIT for 5 consecutive years, with -$2.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBIT fell 41.38% year-over-year to -$2.3 million in Q2 2026; TTM through Jun 2026 was -$8.6 million, a 11.79% decrease from a year earlier, with the FY2025 full-year figure at -$7.8 million, up 20.14% from the prior year.
• EBIT was -$2.3 million for Q2 2026 at 60 Degrees Pharmaceuticals, down from -$2.1 million in the prior quarter.
• Over five years, EBIT peaked at -$215116.0 in Q3 2022 and troughed at -$4.2 million in Q2 2024.
• A 5-year average of -$1.7 million and a median of -$1.9 million in 2023 frame the typical range for EBIT.
• Across the five-year window, EBIT tumbled 607.41% in 2023 and surged 61.65% in 2025, its largest moves.
• Over 5 years, EBIT stood at -$684698.0 in 2022, then tumbled by 176.64% to -$1.9 million in 2023, then decreased by 9.03% to -$2.1 million in 2024, then rose by 7.16% to -$1.9 million in 2025, then fell by 18.45% to -$2.3 million in 2026.
• The last three EBIT figures came in at -$2.3 million (Q2 2026), -$2.1 million (Q1 2026), and -$1.9 million (Q4 2025), per Business Quant data.